Hyperfibrinolysis during liver transplantation is associated with bleeding

• References

• 1 Kang YG, Martin DJ, Marquez J. et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888-896.
• 2 Dzik WH, Arkin CF, Jenkins RL. et al. Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator. Blood 1988; 71: 1090-1095.
• 3 Segal HC, Hunt BJ, Cottam S. et al. Changes in the contact system during orthotopic liver transplantation with and without aprotinin. Transplantation 1995; 59: 366-370.
• 4 Lisman T, Leebeek FWG, Mosnier LO, et al. Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis. Gastroenterology 2001; 121: 131-139.
• 5 Rijken DC, Kock EL, Guimarães AHC. et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 2116-2122.
• 6 Colucci M, Binetti BM, Branca MG. et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38: 230-237.
• 7 Tripodi A, Salerno F, Chantarangkul V. et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-558.
• 8 Wang Y, Liu Y, Han R. et al. Hemostatic variation during perioperative period of orthotopic liver transplantation without venovenous bypass. Thromb Res 2008; 122: 161-166.
• 9 Roullet S, Pillot J, Freyburger G. et al. Rotation thromboelastometry detects thrombocytopenia and hypofibrinogenaemia during orthotopic liver transplantation. Br J Anaesth 2010; 104: 422-428.
• 10 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Prog Chem Fibrinolysis Thrombolysis, vol 2. New York: Ravens Press; 1976. pp. 57-65.
• 11 Levrat A, Gros A, Rugeri L. et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100: 792-797.
• 12 Surawong A, Rojnuckarin P, Juntiang J. et al. Hyperfibrinolysis and the risk of hemorrhage in stable cirrhotic patients. Asian Biomed 2010; 04: 199-206.
• 13 Sié P, Steib A. Central laboratory and point of care assessment of perioperative hemostasis. Can J Anaesth 2006; 53: S12-S20.
• 14 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436.
• 15 Eriksson E, Ranby M, Gyzander E. et al. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 1988; 50: 91-101.
• 16 Declerck PJ, Alessi MC, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225.
• 17 Bos R, Hoegee-de Nobel E, Laterveer R. et al. A one-step enzyme immunoassay for the determination of total tissue-type plasminogen activator (t-PA) antigen in plasma. Blood Coagul Fibrinolysis 1992; 03: 303-307.
• 18 Brogren H, Wallmark K, Deinum J. et al. Platelets Retain High Levels of Active Plasminogen Activator Inhibitor 1. PLoS ONE 2011; 06: e26762.
• 19 Segal H, Cottam S, Potter D. et al. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997; 25: 683-688.
• 20 Porte RJ, Bontempo FA, Knot EA. et al. Tissuetype-plasminogen-activator-associated fibrinolysis in orthotopic liver transplantation. Transpl Proc 1989; 21: 3542.
• 21 Pereboom IT, Adelmeijer J, van Leeuwen Y. et al Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. Am J Transpl 2009; 09: 1189-1196.
• 22 Segal HC, Hunt BJ, Cottam S. et al. Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin. Transplantation 1994; 58: 1356-1360.
• 23 Hunt BJ, Cottam S, Segal H. et al. Inhibition by aprotinin of tPA-mediated fibrinolysis during orthotopic liver transplantation. Lancet 1990; 336: 381.
• 24 Mimuro J, Mizuta K, Kawano Y. et al. Impact of acute cellular rejection on coagulation and fibrinolysis biomarkers within the immediate post-operative period in pediatric liver transplantation. Pediatr Transpl 2010; 14: 369-376.
• 25 Kluft C. Constitutive synthesis of tissue type plasminogen activator and plasminogen activator inhibitor type 1: conditions and therapeutic targets. Fibrinolysis 1994; 08 (Suppl. 02) 1-7.
• 26 Porte RJ, Bontempo FA, Knot EA. et al. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989; 47: 978-984.
• 27 Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. Clin Liver Dis 2009; 13: 21-31.
• 28 Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: Lessons from the liver. Thromb Haemost 2008; 100: 992-1006.
• 29 Schofield N, Sugavanam A, Thompson K. et al. No increase in blood transfusions during liver transplantation since the withdrawal of aprotinin. Liver Transpl 2014; 20: 584-590.
• 30 Steib A, Gengenwin N, Freys G. et al. Predictive factors of hyperfibrinolytic activity during liver transplantation in cirrhotic patients. Br J Anaesth 1994; 73: 645-648.
• 31 Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007; 46: 727-733.
• 32 Tripodi A, Mannucci PM. The Coagulopathy of Chronic Liver Disease. N Engl J Med 2011; 365: 147-156.